Mineralys Stock Rises on Lorundrostat Trial Success

Mineralys Therapeutics reported successful results from its pivotal trials for lorundrostat, a drug targeting uncontrolled or resistant hypertension, achieving significant reductions in blood pressure. The Launch-HTN Phase 3 trial demonstrated a reduction in systolic blood pressure by 16.9 mmHg at 6 weeks and 19.0 mmHg at 12 weeks for patients taking a 50 mg dose. The Advance-HTN Phase 2 trial also showed a placebo-adjusted reduction of 7.9 mmHg at 12 weeks. These results, combined with a favorable safety profile, highlight lorundrostat's potential as a transformative treatment option. As a result, Mineralys' stock rose significantly, reaching a 52-week high. Lorundrostat, an aldosterone synthase inhibitor, offers a modern approach to managing hypertension by reducing aldosterone levels, with fewer side effects compared to older therapies like spironolactone.